| Hypertension and diabetes mellitus: coprediction and time trajectories V Tsimihodimos, C Gonzalez-Villalpando, JB Meigs, E Ferrannini Hypertension 71 (3), 422-428, 2018 | 278 | 2018 |
| Dyslipidemia associated with chronic kidney disease V Tsimihodimos, Z Mitrogianni, M Elisaf The open cardiovascular medicine journal 5, 41, 2011 | 236 | 2011 |
| Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB V Tsimihodimos, SAP Karabina, AP Tambaki, E Bairaktari, ... Arteriosclerosis, thrombosis, and vascular biology 22 (2), 306-311, 2002 | 219 | 2002 |
| Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment V Tsimihodimos, E Dounousi, KC Siamopoulos American journal of nephrology 28 (6), 958-973, 2008 | 215 | 2008 |
| Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Small, Dense LDL Particles in Human Plasma I Gazi, ES Lourida, T Filippatos, V Tsimihodimos, M Elisaf, AD Tselepis Clinical chemistry 51 (12), 2264-2273, 2005 | 208 | 2005 |
| A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease AA Kei, TD Filippatos, V Tsimihodimos, MS Elisaf Metabolism 61 (7), 906-921, 2012 | 171 | 2012 |
| Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia V Tsimihodimos, SAP Karabina, AP Tambaki, E Bairaktari, G Miltiadous, ... Journal of lipid research 43 (2), 256-263, 2002 | 165 | 2002 |
| Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins V Tsimihodimos, A Kakafika, AP Tambaki, E Bairaktari, MJ Chapman, ... Journal of lipid research 44 (5), 927-934, 2003 | 160 | 2003 |
| Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles IF Gazi, V Tsimihodimos, AD Tselepis, M Elisaf, DP Mikhailidis Expert opinion on biological therapy 7 (1), 53-72, 2007 | 148 | 2007 |
| Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia M Kalogirou, V Tsimihodimos, I Gazi, T Filippatos, V Saougos, ... Current medical research and opinion 23 (5), 1169-1176, 2007 | 131 | 2007 |
| Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia M Elisaf, V Tsimichodimos, E Bairaktari, KC Siamopoulos Journal of cardiovascular pharmacology 34 (1), 60-63, 1999 | 120 | 1999 |
| The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic V TSIMIHODIMOS, E BAIRAKTARI, C TZALLAS, G MILTIADUS, ... Thyroid 9 (4), 365-368, 1999 | 120 | 1999 |
| Fenofibrate: metabolic and pleiotropic effects V Tsimihodimos, G Miltiadous, SS Daskalopoulou, DP Mikhailidis, ... Current vascular pharmacology 3 (1), 87-98, 2005 | 115 | 2005 |
| Clinical and laboratory characteristics of hypernatraemia in an internal medicine clinic G Liamis, V Tsimihodimos, M Doumas, A Spyrou, E Bairaktari, M Elisaf Nephrology Dialysis Transplantation 23 (1), 136-143, 2008 | 104 | 2008 |
| Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education … I Gazi, V Tsimihodimos, T Filippatos, E Bairaktari, AD Tselepis, M Elisaf Metabolism 55 (7), 885-891, 2006 | 104 | 2006 |
| Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome KG Lagos, TD Filippatos, V Tsimihodimos, IF Gazi, C Rizos, AD Tselepis, ... Lipids 44, 9-16, 2009 | 93 | 2009 |
| Disturbances of phosphate metabolism: another feature of metabolic syndrome R Kalaitzidis, V Tsimihodimos, E Bairaktari, KC Siamopoulos, M Elisaf American journal of kidney diseases 45 (5), 851-858, 2005 | 89 | 2005 |
| Lipidomics in non-alcoholic fatty liver disease S Kartsoli, CE Kostara, V Tsimihodimos, ET Bairaktari, DK Christodoulou World Journal of Hepatology 12 (8), 436, 2020 | 85 | 2020 |
| Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values V Tsimihodimos, A Kostoula, A Kakafika, E Bairaktari, AD Tselepis, ... Journal of cardiovascular pharmacology and therapeutics 9 (1), 27-33, 2004 | 78 | 2004 |
| Pleiotropic effects of ezetimibe: do they really exist? M Kalogirou, V Tsimihodimos, M Elisaf European journal of pharmacology 633 (1-3), 62-70, 2010 | 73 | 2010 |
